Mini Review
Curcumin analogs: Their roles in pancreatic cancer growth and metastasis
Ganji Purnachandra Nagaraju,
Leah Benton,
Shipra Reddy Bethi,
Mamoru Shoji,
Bassel F. El-Rayes,
Ganji Purnachandra Nagaraju
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Search for more papers by this authorLeah Benton
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Search for more papers by this authorShipra Reddy Bethi
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Search for more papers by this authorMamoru Shoji
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Search for more papers by this authorCorresponding Author
Bassel F. El-Rayes
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Correspondence to: Bassel F. El-Rayes, MD, 1365 Clifton RD NE, Office 2080, Atlanta, GA 30322, E-mail: [email protected]; Tel.: 404-778-5419; Fax: 404-778-5520Search for more papers by this authorGanji Purnachandra Nagaraju,
Leah Benton,
Shipra Reddy Bethi,
Mamoru Shoji,
Bassel F. El-Rayes,
Ganji Purnachandra Nagaraju
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Search for more papers by this authorLeah Benton
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Search for more papers by this authorShipra Reddy Bethi
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Search for more papers by this authorMamoru Shoji
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Search for more papers by this authorCorresponding Author
Bassel F. El-Rayes
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Correspondence to: Bassel F. El-Rayes, MD, 1365 Clifton RD NE, Office 2080, Atlanta, GA 30322, E-mail: [email protected]; Tel.: 404-778-5419; Fax: 404-778-5520Search for more papers by this authorConflicts of interest: Dr. Mamoru Shoji is one of the patent holders (US Patent Number 6,664,272) for curcumin analogs. The rest of the authors disclose no conflicts of interest.
Abstract
Curcumin is a polyphenolic constituent of turmeric that is known to have various molecular effects in preclinical models, leading to prevention and anticancer properties. In clinical trials, curcumin has failed to demonstrate activity against pancreatic cancer possibly due to its low bioavailability and potency. Using the curcumin molecular model, our group and others have synthesized several analogs with better bioavailability and higher potency in pancreatic cancer in vitro and xenograft models. This mini review summarizes some of the known molecular effects of curcumin analogs and their potential role as novel therapeutics for pancreatic cancer.
References
- 1Tang S-C, Chen Y-C. Novel therapeutic targets for pancreatic cancer. World J Gastroenterol 2014; 20: 10825–10844.
- 2Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev 2014; 40: 1039–1047.
- 3Apte M, Pirola R, Wilson J. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol 2012; 3: 344.
- 4Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 2015; 47: 1168–1178.
- 5Moir JA, Mann J, White SA. The role of pancreatic stellate cells in pancreatic cancer. Surg Oncol 2015; 24: 232–238.
- 6Kikuta K, Masamune A, Watanabe T, et al. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun 2010; 403: 380–384.
- 7Mihaljevic AL, Michalski CW, Friess H, et al. Molecular mechanism of pancreatic cancer—understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg 2010; 395: 295–308.
- 8Tang D, Wang D, Yuan Z, et al. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma. Int J Cancer 2013; 132: 993–1003.
- 9Wu YS, Chung I, Wong WF, et al. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells. Biochim Biophys Acta 2017; 1861: 296–306.
- 10Tian L, Lu Z-P, Cai B-B, et al. Activation of pancreatic stellate cells involves an EMT-like process. Int J Oncol 2016; 48: 783–792.
- 11Zhou P, Li B, Liu F, et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. Mol Cancer 2017; 16: 52.
- 12Epelbaum R, Schaffer M, Vizel B, et al. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010; 62: 1137–1141.
- 13Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. J Surg Oncol 2017; 116: 25–34.
- 14Mathew A, Bahary N. Systemic therapy in pancreatic cancer. Multidisciplinary Management of Gastrointestinal Cancers. World Scientific 2017; 247. –273.
- 15Wang F, Kumar P. The role of radiotherapy in management of pancreatic cancer. J Gastrointest Oncol 2011; 2: 157–167.
- 16Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199–225.
- 17Masamune A, Suzuki N, Kikuta K, et al. Curcumin blocks activation of pancreatic stellate cells. J Cell Biochem 2006; 97: 1080–1093.
- 18Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741–4751.
- 19Bao B, Wang Z, Ali S, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res 2012; 5: 355–364.
- 20Bao B, Ali S, Banerjee S, et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012; 72: 335–345.
- 21Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807–818.
- 22Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007; 28: 1765–1773.
- 23Yang H, Fan S, An Y, et al. Bisdemethoxycurcumin exerts pro-apoptotic effects in human pancreatic adenocarcinoma cells through mitochondrial dysfunction and a GRP78-dependent pathway. Oncotarget 2016; 7: 83641.
- 24Russo M, Spagnuolo C, Tedesco I, et al. Phytochemicals in cancer prevention and therapy: truth or dare? Toxins 2010; 2: 517–551.
- 25Syng-Ai C, Kumari AL, Khar A. Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol Cancer Ther 2004; 3: 1101–1108.
- 26Shishodia S, Chaturvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer 2007; 31: 243–305.
- 27Wang Z, Zhang Y, Banerjee S, et al. Retracted: Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006; 106: 2503–2513.
- 28Sahu R, Batra S, Srivastava S. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer 2009; 100: 1425–1433.
- 29Zhao Z, Li C, Xi H, et al. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway. Mol Med Rep 2015; 12: 5415–5422.
- 30Zhao C, Liu Z, Liang G. Promising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs). Curr Pharm Des 2013; 19: 2114–2135.
- 31Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem Pharmacol 2008; 76: 1590–1611.
- 32Anand P, Kunnumakkara AB, Newman RA, et al. Bioavilability of curcumin: problems and promises. Mol Pharm 2007; 4: 807–818.
- 33Lin L, Hutzen B, Zuo M, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70: 2445–2454.
- 34Ireson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev 2002; 11: 105–111.
- 35Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008; 17: 1411–1417.
- 36Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 2014; 46: 2–18.
- 37Kurien BT, Singh A, Matsumoto H, et al. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol 2007; 5: 567–576.
- 38Kurien BT, Harris VM, Quadri SM, et al. Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr/lpr mice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatment. Lupus Sci Med 2015; 2: e000114.
- 39Bao B, Ali S, Kong D, et al. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PloS One 2011; 6: e17850.
- 40Bao B, Ali S, Ahmad A, et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PloS One 2012; 7: e50165.
- 41Nagaraju GP, Zhu S, Wen J, et al. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett 2013; 341: 195–203.
- 42Nagaraju GP, Zhu S, Ko JE, et al. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. Cancer Lett 2015; 357: 557–565.
- 43Adams BK, Ferstl EM, Davis MC, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 2004; 12: 3871–3883.
- 44Yamaguchi M, Moore TW, Sun A, et al. Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-κB inhibition. Integr Biol 2012; 4: 905–913.
- 45Rajitha B, Nagaraju GP, Shaib WL, et al. Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. Mol Carcinog 2017; 56: 288–299.
- 46Rajitha B, Belalcazar A, Nagaraju GP, et al. Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. Cancer Lett 2016; 373: 227–233.
- 47Sankpal UT, Nagaraju GP, Gottipolu SR, et al. Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species. Oncotarget 2016; 7: 3186–3200.
- 48Bisht S, Schlesinger M, Rupp A, et al. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. J Nanobiotechnol 2016; 14: 57.
- 49Kasinski AL, Du Y, Thomas SL, et al. Inhibition of IκB kinase-nuclear factor-κB signaling pathway by 3, 5-bis (2-flurobenzylidene) piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 2008; 74: 654–661.
- 50Landais I, Hiddingh S, McCarroll M, et al. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Mol Cancer 2009; 8: 133–145.
- 51van der Heijden MS, Brody JR, Dezentje DA, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005; 11: 7508–7515.
- 52Reid JM, Buhrow SA, Gilbert JA, et al. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone, 3, 5-bis [(2-fluorophenyl) methylene]-acetate (3E, 5E)(EF-24; NSC 716993). Cancer Chemother Pharmacol 2014; 73: 1137–1146.
- 53Lagisetty P, Subramaniam D, Sahoo K, et al. Anticancer activity of an Imageable Curcuminoid 1-[2-Aminoethyl-(6-hydrazinopyridine-3-carbamidyl)-3, 5-bis-(2-fluorobenzylidene)-4-piperidone (EFAH)]. Chem Biol Drug Des 2012; 79: 194–201.
- 54Saglam ASY, Yilmaz A, Onen HI, et al. HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells. EXCLI J 2016; 15: 246–255.
- 55Dinkova-Kostova AT, Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of phase 2 detoxification enzymes. Carcinogenesis 1999; 20: 911–914.
- 56Dragovich PS, Prins TJ, Zhou R, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem 2003; 46: 4572–4585.
- 57H Johansson M. Reversible Michael additions: covalent inhibitors and prodrugs. Mini-Rev Med Chem 2012; 12: 1330–1344.
- 58Na HK, Surh YJ. Transcriptional regulation via cysteine thiol modification: a novel molecular strategy for chemoprevention and cytoprotection. Mol Carcinog 2006; 45: 368–380.
- 59Lushchak VI. Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids 2012; 2012: 1–26.
- 60Adams BK, Cai J, Armstrong J, et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 2005; 16: 263–275.
- 61Sun A, Lu YJ, Hu H, et al. Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism. Bioorg Med Chem Lett 2009; 19: 6627–6631.
- 62Dinkova-Kostova AT, Massiah MA, Bozak RE, et al. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci 2001; 98: 3404–3409.
- 63Hutzen B, Friedman L, Sobo M, et al. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int J Oncol 2009; 35: 867–872.
- 64Sato A, Kudo C, Yamakoshi H, et al. Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis. Cancer Sci 2011; 102: 1045–1051.
- 65Friedman L, Lin L, Ball S, et al. Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. Anticancer Drugs 2009; 20: 444–449.
- 66Ali S, Ahmad A, Banerjee S, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606–3607.
- 67Padhye S, Yang H, Jamadar A, et al. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res 2009; 26: 1874–1880.
- 68Lin L, Hutzen B, Ball S, et al. New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci 2009; 100: 1719–1727.
Citing Literature
